Want to see AKTS full AI Analyst Report?
AKTS Stock Chart & Stats
$20.25
--
Market closed
$20.25
--
Day’s Range― - ―
52-Week Range$14.72 - $34.19
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$1.33B
Enterprise Value$896.56M
Total Cash (Recent Filing)$538.48M
Total Debt (Recent Filing)$11.58M
Price to Earnings (P/E)―
Beta2.20
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding53,404,617
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio3.39
Price to Book (P/B)-8.05
Price to Sales (P/S)181.08
P/FCF Ratio-15.96
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue175.90
Enterprise Value/Gross Profit201.70
Enterprise Value/Ebitda-27.92
Forecast
1Y Price Target
$35.50Price Target Upside75.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrendA 596% revenue increase in 2025 indicates accelerating commercial traction or successful early product uptake versus 2024. Sustained top-line growth from a low base can validate product-market fit, support scale-up, and improve future gross margin leverage if growth persists over the next several quarters.
Reported Strong Gross MarginConsistently strong gross margins suggest the core product or service has favourable unit economics and pricing power. If maintained while revenues scale, strong gross margins provide durability to profitability efforts and reduce the cash needed per dollar of revenue as the business grows.
Modest Absolute DebtRelatively low nominal debt gives the company flexibility versus highly leveraged peers, limiting fixed financial obligations. With manageable debt levels, management can prioritize operational investment or R&D without immediate refinancing pressure, reducing near-term solvency risk.
Bears Say
Large Net LossesVery large net losses relative to revenue indicate the company remains in deep investment mode and far from breakeven. Persistent high operating losses consume cash and require external funding, increasing execution and dilution risk unless growth leads to rapid margin improvement.
Negative Shareholders' EquityDeepening negative equity signals accumulated deficits and weakened balance sheet solvency. Negative equity constrains financing options, raises creditor and investor concerns, and makes the company more reliant on dilutive equity raises or costly financing to fund operations over the medium term.
Return To Heavy Cash BurnA sharp reversal from positive FCF in 2024 to significant cash burn in 2025 materially increases near-term funding needs. Sustained negative FCF elevates refinancing and execution risk, and requires reliable access to capital markets or partnerships to maintain R&D and commercialization efforts.
Aktis Oncology, Inc. News
AKTS FAQ
What was Aktis Oncology, Inc.’s price range in the past 12 months?
Aktis Oncology, Inc. lowest stock price was $14.72 and its highest was $34.19 in the past 12 months.
What is Aktis Oncology, Inc.’s market cap?
Aktis Oncology, Inc.’s market cap is $1.33B.
When is Aktis Oncology, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aktis Oncology, Inc.’s earnings last quarter?
Currently, no data Available
Is Aktis Oncology, Inc. overvalued?
According to Wall Street analysts Aktis Oncology, Inc.’s price is currently Undervalued.
Does Aktis Oncology, Inc. pay dividends?
Aktis Oncology, Inc. does not currently pay dividends.
What is Aktis Oncology, Inc.’s EPS estimate?
Aktis Oncology, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aktis Oncology, Inc. have?
Aktis Oncology, Inc. has 53,404,617 shares outstanding.
What happened to Aktis Oncology, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aktis Oncology, Inc.?
Currently, no hedge funds are holding shares in AKTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aktis Oncology, Inc. Stock Smart Score
Company Description
Aktis Oncology, Inc.
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
AKTS Stock 12 Month Forecast
Average Price Target
$35.50
▲(75.31% Upside)
Iovance Biotherapeutics
―
Zymeworks
―
Oric Pharmaceuticals
―
Immunocore Holdings
―
Nanobiotix
―
Ownership Overview
47.63% Insiders
4.33% Mutual Funds
7.99% Other Institutional Investors
36.24% Public Companies and
Individual Investors